Breaking News

BioMagnetic Solutions will supply research and cGMP manufacturing grade FerroSelect reagents to Lonza for use in developing CAR-T and other immunotherapeutics.

10.14.22

The collaboration provides a framework for additional clinical grade reagents to be developed and opens up the possibility of other collaborations as Gamma Biosciences expands its portfolio of tools and technologies supporting the bioprocessing, vaccine, cell and gene therapy industries.

"We are looking forward to working together with the team at Gamma Biosciences to offer cell and gene therapy developers added cell selection functionality on the Cocoon Platform" said Adam Bryan, Vice President of Personalized Medicines at Lonza. "The BioMagnetic Solutions ferrofluid technology provides efficient, high-performance cell selection reagents for research, clinical, and commercial-scale cell separations in a workflow that can be easily integrated into our automated, closed-system Cocoon manufacturing platform. This collaboration speaks to Lonza's commitment to expanding the flexibility and functionality of our automated manufacturing technology to address a broader range of needs for the cell therapy industry."

"We are thrilled to collaborate with Lonza in further developing and adapting FerroSelect reagents for use with the Cocoon Platform," said Phil Vanek, Chief Technology Officer at Gamma Biosciences. "The Lonza platform can be an alternative to our FerroSelect Array cell selection platform, demonstrating that our proprietary reagents can be applied to other automated manufacturing technologies. The agreement gives BioMagnetic Solutions technical direction on new applications, and access to some of the best process developers in the industry. In return, Lonza gains early access to certain BioMagnetic Solutions FerroSelect reagents to complement the growing demand for their Cocoon Platform technology."

Excerpt from:

Gamma Biosciences, Lonza Enter Cell and Gene Therapy Alliance - Contract Pharma